CIS Pharma has developed contact lens care products based on its new patented technology platform
Bubendorf, Switzerland, Friday, June 16, 2016 - CIS Pharma has developed a novel multipurpose solution for contact lenses. With over 25 years of experience and a track record of several lens care products licensed to and sold by partners globally, the team has developed the next generation contact lens care solution that increases contact lens wear comfort while keeping the [...]
Approval received for intracameral cefuroxime for antibiotic prophylaxis of endophthalmitis after cataract surgery
Uppsala, Sweden, Mai 24, 2016 – The marketing authorization application for intracameral cefuroxime has been finalized with a positive outcome. The decentralized procedure was led by Sweden as reference member states with a total of seventeen reference member states across Europe. As a result, a large number of cataract clinics in Europe will benefit from the intracameral injection of cefuroxime [...]
Development of vial adaptor for preparation of intracameral cefuroxime
Bubendorf, April 10, 2016 – CIS Pharma enters agreement with West Pharma to develop a vial adaptor specific for the preparation and injection of intracameral cefuroxime. The development is innovative device that prevents the 10mg/ml cefuroxime sodium solution from particulate contamination, containing several 5-micron filters. After reconstitution of the cefuroxime powder, the vial adaptor separates into two parts, immediately offering [...]
CIS Pharma team attends Pharmapack 2016 in Paris
Paris, France, Wednesday to Thursday, February 10 to 11, 2016 – CIS Pharma is attending CPhI Worlwide to meet development partners and licensees during the two-day conference in Paris. The team is setting out to meet face-to-face project partners and to source solutions for their innovation projects. As a number of meetings are scheduled we are kindly asking to confirm [...]
CIS Pharma announces the first milestones in its ADC research program are achieved
Bubendorf, Switzerland, Thursday, January 21, 2016 - Proof of concept studies at NBE Therapeutics demonstrated conjugation of CIS Pharma’s Cellophil® Smart Polymer drug carrier to antibodies. Consequently, different linkers were evaluated for loading the drug carrier with anti-cancer moieties. CIS Pharma has successfully loaded its proprietary Cellophil® Smart Polymer drug carriers with model compounds for cancer therapies. CIS Pharma [...]
CIS Pharma creates novel contact lens coating technology
Bubendorf, Switzerland, Tuesday, November 17, 2015 - CIS Pharma is expanding its Cellophil® Smart Polymer platform with new bio-inspired derivatives. The derivatives are used as building blocks for the development of a novel contact lens coating technology. The Cellophil® Smart Polymer coating technology aims to improve the wettability of silicone hydrogel contact lenses. In addition, the coating is designed to [...]
CIS Pharma team attends CPhI Worlwide 2015 in Madrid
Madrid, Spain, Tuesday to Thursday, October 13 to 15, 2015 – CIS Pharma is attending CPhI Worlwide to meet development partners and licensees during the three-day conference in Madrid. The team is setting out to meet face-to-face project partners and to source solutions for their innovation projects. As a number of meetings are scheduled we are kindly asking to confirm [...]
CIS Pharma develops solubilization technology for hydrophobic drugs
Bubendorf, Switzerland, Tuesday, September 2, 2015 - CIS Pharma has engaged in a research program to develop a new technology platform that creates water-soluble formulations of highly hydrophobic drugs. The approach comprises a polymer-based solubilization technology that can be applied to a large number of water-insoluble drugs. The technology aims to improve the bioavailability and tolerance for drugs used in [...]
Submission of marketing authorization application for intracameral cefuroxime completed
Uppsala, Sweden, July 20, 2015 – CIS Pharma has submitted to the Swedish competent authority MPA the marketing authorization application for intracameral cefuroxime. The decentralized procedure is led by Sweden as reference member states with a total of seventeen reference member states across Europe. The CIS Pharma team is proud to have achieved the first major milestone in the agreement [...]
CIS Pharma creates next generation contact lens care products
Bubendorf, Switzerland, Friday, June 12, 2015 - CIS Pharma is investigating novel formulations and combinations of active ingredients to improve contact lens care. With over 25 years of experience and a track record of several lens care products licensed to and sold by partners globally, the team is targeting a novel concept that allows for higher contact lens wear comfort [...]
CIS Pharma appoints Davide Panighetti to its cancer research team
Bubendorf, Switzerland, Monday, March 23, 2015 - CIS Pharma welcomes Davide Panighetti, who reinforces the research team as a new synthesis chemist. Davide’s skills will boost the team working on proprietary polymer-drug carrier developed for antibody-drug conjugates and antibody-radionuclide conjugates. The polymer-drug carriers are based on the CIS Pharma's proprietary polymer technology allowing ADCs to be custom designed for delivery [...]
CIS Pharma team attends Pharmapack 2015 in Paris
Paris, France, Wednesday to Thursday, February 11 to 12, 2015 – CIS Pharma is attending CPhI Worlwide to meet development partners and licensees during the two-day conference in Paris. The team is setting out to meet face-to-face project partners and to source solutions for their innovation projects. As a number of meetings are scheduled we are kindly asking to confirm [...]
CIS Pharma to develop drug carriers for ADCs
Bubendorf, Switzerland, Monday, January 12, 2015 - CIS Pharma has taken a strategic decision to extend its activity into the field of cancer treatments. The defined objective is to improve the potency of antibody-drug conjugates (ADCs). Having established a number of lead materials, the research team is now developing drug carriers that offer higher drug load per antibody as compared [...]
CIS Pharma signs development and licensing agreement with marketing partner for cefuroxime
Bubendorf, Switzerland, October 12, 2014 – CIS Pharma signs development and licensing agreement with licensee. Having developed intracameral cefuroxime as a response to the clinical demand for such a product, CIS Pharma is proud to have signed a deal on the regulatory approval and distribution of its product. Also, the deal includes a license to CIS Pharma’s patent protected cefuroxime [...]